Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
about
Probiotics for maintenance of remission in ulcerative colitisFrom structure to function: the ecology of host-associated microbial communitiesThe intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directionsBugging inflammation: role of the gut microbiotaTHE INTESTINAL MICROBIOTA AND THE ROLE OF PROBIOTICS IN IRRITABLE BOWEL SYNDROME: a reviewThe use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American expertsUlcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrierGut microbial flora, prebiotics, and probiotics in IBD: their current usage and utilityThe role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trialsIntestinal microbiota in health and disease: role of bifidobacteria in gut homeostasisProbiotics in inflammatory bowel diseases and associated conditionsIntestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel diseaseIntestinal permeability--a new target for disease prevention and therapyMicrobiota biodiversity in inflammatory bowel diseaseProbiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathologyModulation of microbiota as treatment for intestinal inflammatory disorders: An uptodateThe Significance of the Enteric Microbiome on the Development of Childhood Disease: A Review of Prebiotic and Probiotic Therapies in Disorders of ChildhoodSystematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel diseaseProbiotic Mix VSL#3 Is Effective Adjunctive Therapy for Mild to Moderately Active Ulcerative ColitisDiet, gut microbes, and the pathogenesis of inflammatory bowel diseases.Evidence for the effects of yogurt on gut health and obesity.An update on the use and investigation of probiotics in health and disease.Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel diseaseEffect of probiotics on clinical and immune parameters in enthesitis-related arthritis category of juvenile idiopathic arthritis.Lactobacillus plantarum prevents the development of colitis in IL-10-deficient mouse by reducing the intestinal permeability.The ecological community of commensal, symbiotic, and pathogenic gastrointestinal microorganisms - an appraisalGut microbiota, probiotics, and human healthProbiotics as therapy in gastroenterology: a study of physician opinions and recommendations.Amelioration of colitis in mouse model by exploring antioxidative potentials of an indigenous probiotic strain of Lactobacillus fermentum Lf1.Intestinal microbiota and health in childhood.The 'hygiene hypothesis' for autoimmune and allergic diseases: an update.Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants.Effects of probiotics and antibiotics on the intestinal homeostasis in a computer controlled model of the large intestine.Protective effects of Lactobacillus plantarum against epithelial barrier dysfunction of human colon cell line NCM460.Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?Recommendations for probiotic use in humans-a 2014 updateEnteric microbiota leads to new therapeutic strategies for ulcerative colitis.Safety assessment of probiotics for human use.Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond.Cocktails of probiotics pre-adapted to multiple stress factors are more robust under simulated gastrointestinal conditions than their parental counterparts and exhibit enhanced antagonistic capabilities against Escherichia coli and Staphylococcus au
P2860
Q24234400-5059433B-4499-4E0E-A853-3D64C4075A7FQ24612050-50CB2DFD-DC79-4A67-9FF5-258E0C9F2BBEQ26745700-77A23406-46BF-4D75-A163-A962A766CBAAQ26748440-F5E9482B-FBC2-4C4A-935A-E1D3F3A4F8FFQ26769725-718FB96F-E664-44BB-868D-EE49832ED1E5Q26823347-B0D3E2CB-FFFF-47B0-8763-CC3B6C4F02C8Q26825483-3F442661-80B9-47C5-9AE8-8FC9D29A26ECQ26995672-2A92CB3C-D83D-4377-9E7D-C3D0A3AA3AF1Q27001546-3725730D-0044-427C-8390-5ABFB6C085BDQ27001712-4B9595BF-C092-47BB-9E6D-BC3504937E5DQ27002496-FB99754A-2517-400E-A487-68649AD2D5D4Q27003192-A8ACEFC0-47D7-4267-B023-B0B29CA16DFAQ27015884-292AF677-7524-44A4-8A74-DCCD606022F6Q27027772-86485D7E-44AB-446F-BE1E-A365721538A5Q27027791-2CC65C85-EF35-4913-A235-A5F8C53A46ACQ28072437-2B7512FD-C092-461D-B5A6-665A12488C13Q28075770-0D384AB5-D999-444B-AFBB-8211909A39DBQ28254207-7830A3A6-AAFB-4340-B7BD-C67BB81FC370Q29037475-8063CA5A-865C-4A31-820C-FCB81EB4D033Q30249313-DBF51DDD-AC1A-4ED6-B0B2-E7C3390E38FAQ30252163-1F05FBD5-9534-426A-8140-B9854B1FCC8CQ30407565-75590B04-E249-424C-81AF-B8E1059B31CBQ30570535-F28B1316-62C8-4864-81BE-C15617F7EEB5Q33468052-A137B22F-3825-44F2-9B43-D2F90071BEFAQ33613698-2D9CBD4C-D1F2-40DF-B945-EFC4913D5151Q33662740-48A34425-6542-464A-9011-CD582FD209CEQ33666412-299839AB-7EE2-461A-8B1E-D0D167B0D507Q33888804-F239D714-B4CE-46E2-9DBC-9C1780E7D18AQ33908943-FB2B55E1-3D57-4C6F-9C1F-5C5ADA69E627Q33920563-A39AA75F-F497-44A5-9167-6699A7D9C188Q34111851-EFBFD7A8-FEAF-425C-A6B6-FC74A8F06695Q34165056-42A1DF64-B400-4D35-8101-7E793CF75BBDQ34209418-B141E6F7-220C-4A55-B021-06EDEDAE39AAQ34385197-BD7B478D-E88D-4B77-AAD5-0D1025689656Q34407175-F028B809-8801-4FF2-B97D-D7A3169574FEQ34411373-504EAEA8-8A0A-4075-A730-80239DA7AABBQ34499080-89AB75FF-1597-4FEB-BD2E-4DFAA759AA97Q34503589-E67C3ABF-688D-46D2-81B5-8A06509217DBQ35000008-33C65534-64AD-4422-84A3-71EC4D91A419Q35132859-8D50DA4A-5F84-4FAE-B818-77178677F377
P2860
Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Effect of a probiotic preparat ...... ldren with ulcerative colitis.
@en
Effect of a probiotic preparation
@nl
type
label
Effect of a probiotic preparat ...... ldren with ulcerative colitis.
@en
Effect of a probiotic preparation
@nl
prefLabel
Effect of a probiotic preparat ...... ldren with ulcerative colitis.
@en
Effect of a probiotic preparation
@nl
P2093
P2860
P356
P1476
Effect of a probiotic preparat ...... ldren with ulcerative colitis.
@en
P2093
Eleonora Giannetti
Erasmo Miele
Filomena Pascarella
Lucia Quaglietta
Robert N Baldassano
P2860
P304
P356
10.1038/AJG.2008.118
P407
P577
2009-01-20T00:00:00Z